![[PAPER]Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques](https://www.oncodesign-services.com/wp-content/webp-express/webp-images/uploads/2024/04/Paper-Highlight-10-1.png.webp)
Abstract:
The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety records. They contain multiple protein antigens that may improve response breadth and can be easily adapted every year to maintain preparedness for future seasonally emerging variants.
Autors :
Mathilde Galhaut, Urban Lundberg, Romain Marlin, Robert Schlegl, Stefan Seidel, Ursula Bartuschka, Jürgen Heindl-Wruss, Francis Relouzat, Sébastien Langlois, Nathalie Dereuddre-Bosquet, Julie Morin, Maxence Galpin-Lebreau, Anne-Sophie Gallouët, Wesley Gros, Thibaut Naninck, Quentin Pascal, Catherine Chapon, Karine Mouchain, Guillaume Fichet, Julien Lemaitre, Mariangela Cavarelli, Vanessa Contreras, Nicolas Legrand, Andreas Meinke & Roger Le Grand
References :
Galhaut, M., Lundberg, U., Marlin, R. et al. Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques. Commun Med 4, 62 (2024).
https://doi.org/10.1038/s43856-024-00488-w
